Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs Advaxis and Merck have formed a partnership to test their experimental prostate cancer drugs, ADXS-PSA and anti PD-1 antibody pembrolizumab, to see if the combination of these two drugs will yield psoitive results in a phase I/II trial in prostate cancer patients who …

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

August 25th, 2014 Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will evaluate the safety and efficacy …

MedImmune and Advaxis partner on immuno-oncology combination clinical trial

July 22, 2014 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine, ADXS-HPV, …

Patient selection & successful outcomes

Dr Robert Petit, Vice President of Clinical Operations and Medical Affairs, Advaxis joined us at the World Vaccine Congress Washington 2012 to answer the following question: Why does patient selection matter? Simply, because each patient factor can impact the outcome. Patient factors can include: age, performance status, gender, race, disease status etc. Critical patient selection factors can vary by disease …